LegoChem Bio Acquires Patent Rights Related to Next-Generation Targeted Anticancer Drugs
[Asia Economy Reporter Ji Yeon-jin] LegoChem Bio announced on the 27th that it has acquired a patent related to 'Antibody-Drug Conjugate (ADC),' a next-generation targeted anticancer agent.
The patent is titled COMPOUNDS COMPRISING SELF-IMMOLATIVE GROUP and covers a proprietary linker technology that enables effective release of anticancer drugs within cancer cells.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Sold Everything Fearing Bankruptcy, Then It Soared 3,900 Times: How a Stock Once Feared for Delisting Became an AI Powerhouse"
- "All Major Corporations Could Leave"... Business Community Fears Overseas Factory Relocation Due to Strike Risks
- 1789 Capital Scales Up 17-Fold with Trump Jr.; Accelerates Investment in AI and Defense
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
The company explained, "By improving the chemical structure of existing linkers, the in vivo stability and drug release of ADCs containing them have been dramatically enhanced, increasing the efficacy of ADC therapeutics while minimizing side effects."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
